Oncologic Surgery Quality

• 2,159 DKG/OnkoZert certified cancer centers with mandatory multidisciplinary tumor boards; 6 NCT sites and 6 OECI Full Members; Cancer Core Europe membership at NCT Heidelberg
• Annual surgical volumes exceed Score 5 threshold: 60,000 colorectal resections, 12,067 lung cancer resections (2018), 21,850+ radical prostatectomies, 7,390+ radical cystectomies
• R0 resection rates: colorectal 91% (exceeds >85% threshold), pancreatic 76% (falls in Score 4 range), liver 77% (falls in Score 4 range)
• 180+ da Vinci robotic systems with 30%+ robotic prostatectomy adoption; HIPEC Munich Protocol at LMU Munich; TORS at 21.4% of university hospitals
• Transparent quality reporting through StuDoQ registries and 15 state cancer registries; competitive CONCORD-2 outcomes (prostate 91.2%, breast 85.3%, colon 64.6% 5-year survival)
• 52,000+ international cancer patients annually with dedicated international patient offices, multilingual staff, and comprehensive care coordination at all major centers

Read the full Germany report →

• Five OECI Comprehensive Cancer Centers (ICO, Vall d'Hebron, CCUN, Jiménez Díaz, Clínic Barcelona) with 11 additional OECI specialized centers; total 16 OECI member institutions
• 286,664 new cancer cases diagnosed annually sustaining massive surgical volumes; REGECOP records 4,159 CRS/HIPEC procedures across 36 hospitals
• Documented outcome metrics: REGECOP 81.7% complete cytoreduction (2.1% perioperative mortality), head and neck 80% negative margin adherence, breast cancer 5-year survival 87.3%
• Hundreds of fellowship-trained oncologic surgeons with subspecialty coverage (hepatobiliary, CRS/HIPEC, thoracic, urological, gynecological, head/neck, pediatric); Fundació Puigvert performs 200+ robotic procedures annually
• 105 da Vinci robotic systems (5th in Europe), HIPEC at 36 hospitals; HM CIOCC operates da Vinci SP, Xi, and HUGO RAS systems
• Quirónsalud achieved JCI Enterprise Accreditation (first hospital chain globally); HM Hospitales served 35,000+ international patients from 164 nationalities in 2024; €18,000–€35,000 pricing substantially below US/UK
• Red flags: geographic concentration in Madrid and Barcelona, heterogeneous outcome reporting across centers, robotic hysterectomy volumes below European recommendations (approximately 8.9 procedures/center/year vs. ≥15 guideline), pancreatic surgery morbidity thresholds higher than international norms (73% vs. 55%)

Read the full Spain report →

• Three OECI-accredited Comprehensive Cancer Centres (Christie, Cambridge, King's Health Partners) plus ESMO/ESGO-designated centers with international recognition
• Over 90% robotic-assisted prostatectomy adoption with 13% year-on-year surgical volume increases; 58,218 prostate diagnoses in 2024 with radical surgery performed at high rates
• NATCAN operates ten national cancer audits with quarterly provider-level performance indicators published from October 2024, representing one of the most comprehensive national cancer surgery outcome monitoring systems globally
• Annual major cancer surgery volumes exceed 50,000 cases (36,886 lung cancer diagnoses with increasing surgical resection; 17,650 oesophagogastric radical surgeries; Cambridge alone performs ~100 pancreatic and ~150 liver resections annually)
• Comprehensive subspecialty coverage: five NHS highly specialised bone sarcoma centres, seventeen soft tissue sarcoma centres, 21 principal paediatric cancer treatment centres, four ovarian cancer centres of excellence, two national HIPEC centres
• Strong medical tourism infrastructure through London Clinic (140+ countries, multilingual services), Royal Marsden private care, and Cleveland Clinic London; private patients bypass NHS waiting-time constraints

Read the full United Kingdom report →

• Four world-class private cancer centers with international accreditation: Hospital Israelita Albert Einstein (JCI continuously since 1999, 7 consecutive certifications), Hospital Sírio-Libanês (ASCO QOPI + 14 certifications), Hospital de Amor Barretos (ESMO Designated Centre), A.C. Camargo Cancer Center (12 integrated disease centers)
• Approximately 1,800 SBCO (Brazilian Society of Surgical Oncology) members with ~200 formal training positions since specialty recognition in 2017
• High surgical volumes: 56+ hospitals performing >999 cancer surgeries annually; 313,531 colorectal surgeries over 10 years; 43 liver resection centers; 12+ HIPEC centers
• Excellent outcome metrics: liver resection mortality 1–3% at major centers; colorectal in-hospital mortality 5.2–6.7% nationally; gastric cancer OS improved at high-complexity centers (24.4 vs. 18 months)
• Extensive advanced technology: 106 da Vinci robotic systems, HIPEC standardized and available at 12+ centers, VATS established at major centers, RARP incorporated into public SUS in 2025

Read the full Brazil report →

• 453 Ministry of Health-designated cancer care hospitals (DCCHs) including flagship institutions (NCC Hospital, NCC Hospital East, Cancer Institute Hospital of JFCR, Shizuoka Cancer Center) far exceeding the 5+ requirement
• 280+ board-certified esophageal surgeons, plus specialty certification systems for gastric (JGCA), hepatobiliary-pancreatic (JSHBPS), and gynecologic oncology (JSGO/JGOG with 1,046 active members), indicating 50+ fellowship-trained oncologic surgeons across all major cancer types
• 895,606 gastrointestinal/abdominal and 220,741 breast surgical procedures registered in National Clinical Database 2023, vastly exceeding 10,000+ annual case threshold
• Pancreatic cancer R0 resection rates 49-63% and HPB/esophageal outcomes generally in 65-85% range; highest gastric cancer 5-year survival 71.1%; falls short of >85% benchmark for major cancer types
• 350+ da Vinci robotic systems installed with National Health Insurance coverage for prostate, gastric, esophageal, rectal, colon, and endometrial cancer surgeries; da Vinci SP approved for colorectal 2023; domestic hinotori robotic system entering clinical use
• ESMO accreditation at 2 centers (NCC Hospital East, Chiba Cancer Center); JMIP accreditation at 69 institutions; CAP laboratory accreditation; Newsweek World's Best Specialized Hospitals in Oncology 2024-2025
• National Clinical Database covering ≥95% of all board-certified surgical operations with published outcome data in international journals and CONCORD-3 survival benchmarking
• Comprehensive international patient services at National Cancer Center Hospital and Cancer Institute Hospital of JFCR with dedicated international teams, interpretation, and care coordination

Read the full Japan report →

• Asan Medical Center ranked among world's top 5 cancer hospitals by Newsweek 2025; Samsung Seoul Hospital ranked 6th globally and 1st in Asia
• 72.9% five-year relative survival rate (2018-2022); stomach cancer survival 77%, compared to 32.4% in US and 21.6% in UK
• 51 da Vinci robotic surgical systems across 40 institutions; over 15,000 robotic surgeries performed in first decade; 10,000 robotic thyroid surgeries at single institution
• Multiple comprehensive cancer centers with dedicated oncologic surgery departments including Asan Medical Center, Samsung Medical Center, Seoul National University Hospital, and National Cancer Center Hospital
• 11,226 international cancer patients in 2019 with dedicated medical tourism infrastructure, 40-70% cost savings versus US/UK/Germany, and multidisciplinary system serving ~5,000 patients annually

Read the full South Korea report →

• King Hussein Cancer Center performs 5,000+ major cancer surgeries annually with dedicated fellowships in surgical oncology, thoracic, gynecologic, and neurosurgical oncology accredited by Jordanian Medical Council, Arab Board, and European Society of Oncological Surgery [Training Programs - King Hussein Cancer Center - 2024]
• Published outcomes: breast cancer Stage I 96% 5-year overall survival, Stage II 91.3%; colorectal cancer 58.2% 5-year survival (exceeding regional comparators); CNS tumors median overall survival 97 months across 2,094 patients [Breast Cancer Care in Jordan - PMC/JCO - 2020; Colorectal Cancer in Jordan - PMC - 2017; CNS Tumors - PMC - 2025]
• Multiple international accreditations: JCI cancer-specific certification (first outside US), OECI membership, CAP laboratory accreditation, Magnet nursing recognition (top 8% globally), AAHRPP research accreditation [King Hussein Cancer Foundation and Center - Wikipedia - 2024]
• Advanced surgical technology: da Vinci robotic surgery system (Jordan's only), NanoKnife irreversible electroporation (first in region), intraoperative MRI Brain Suite, HIPEC/cytoreductive surgery program [Our Features - King Hussein Cancer Center - 2024]
• Comprehensive international patient infrastructure: dedicated International Patients Office with visa facilitation, airport medical coordination, multi-language translation (English, French, Kurdish), accommodation assistance; treatment costs 25-40% below Western Europe/US [Additional Services for Arab and International Patients - KHCC - 2024; Why Jordan Is Medical Tourism Hotspot - Travel and Tour World - 2026]

Read the full Jordan report →

• 6 JCI-accredited hospitals across Bogotá, Medellín, Cali, Bucaramanga; INC is first Latin American OECI associate member
• NSCLC R0 resection 87.7% at Fundación Santa Fe; breast-conserving surgery 95.4% 5-year overall survival (12.7% margin positivity vs 21.6% US)
• Fundación Santa Fe HIPEC program: JCI-certified, 1,000+ cases, 80% ten-year overall survival, <1% procedural mortality
• Hospital Pablo Tobón Uribe hepatobiliary team: 3 surgeons, 550+ hepatectomies, 450+ pancreatectomies; 5 da Vinci robotic systems in use since 2012
• 70% of oncology services concentrated in 3 regions; only 9.8% of colon cancer patients nationally reach high-volume hospitals

Read the full Colombia report →

• Tata Memorial Centre umbrella includes 10+ cancer institutes; HCG operates 21 comprehensive cancer centers with standardized protocols; multiple other major centers (Apollo, Fortis, Max, SSO, Nanavati, Kokilaben, Manipal)
• AIIMS trained 150+ cancer surgeons over 25 years; MCh Surgical Oncology programs with 6 annual intake at AIIMS; Fellowship programs across 25 renowned centers for specialized oncology
• AIIMS performs 2,000 major cancer surgeries annually; ACTREC performed 1,514 major surgeries in 2018 across all specialties; National Cancer Grid treats 750,000 new cancer patients annually across 244 centers
• Premier institution outcomes: 94.1% five-year overall survival for breast cancer, <5% 30-day mortality for esophageal/rectal/pancreatic cancers, 85-92% survival for early-stage prostate cancer
• Extensive robotic surgery: Manipal Hospital 3,000+ robotic cancer surgeries, Kokilaben 630+ with da Vinci Xi, robotic capabilities for colorectal, endometrial, gastric cancers across multiple centers
• Comprehensive medical tourism infrastructure with 600,000+ international patients annually; services include online consultation, tumor board before arrival, translators, visa assistance, follow-up coordination; cancer treatment costs 60-80% less than Western countries
• However, national-level outcomes significantly lag: only 30% five-year survival nationally vs. 60% in North America/Western Europe; HIPEC complications 7.29% 30-day mortality vs. 0-12% at experienced centers; no OECI or equivalent cancer-specific international accreditation mentioned

Read the full India report →

• INCan is ESMO-accredited comprehensive cancer center treating 5,000+ new patients annually with 172 dedicated oncology beds
• Approximately 250 surgical oncology residents trained yearly at INCan in formal fellowship programs (exceeds 20+ threshold for Score 4)
• Da Vinci robotic surgical systems available at multiple leading hospitals including Médica Sur, ABC Medical Center, and Ángeles hospital chain
• 90.4% five-year overall survival for breast cancer at Hospital de Oncología IMSS, comparable to developed countries
• 5.5% postoperative mortality for complex pancreatic (Whipple) procedures, comparable to high-volume referral centers
• JCI accreditation at 9 hospitals in Mexico including Médica Sur since 2014, and partnership with Mayo Clinic Care Network
• Well-developed medical tourism infrastructure with coordination services, 1.2+ million annual medical tourists, and 45-75% cost savings
• Significant quality variability and healthcare system fragmentation documented as major limitation affecting outcomes consistency

Read the full Mexico report →

• 2 OECI-accredited cancer centers (MSCNRIO full member, Greater Poland Cancer Centre associate) plus 16 regional oncology network hospitals
• 300+ robotic-trained surgeons across subspecialties (200+ urologists, ~60 colorectal, ~30 gynecologic); ESO Clinical Training Centre at MSCNRIO
• Annual volumes: Greater Poland ~7,000 surgeries/year; 10,110 robotic cancer procedures in 2023
• Laparoscopic liver R0 resection rate 89.6%, perioperative mortality 0.8%; lung cancer 5-year survival 56% at academic centers
• 80 hospitals with surgical robots nationally; proton therapy at Greater Poland Cancer Centre; multidisciplinary tumor boards following ESMO guidelines; 40%+ international patient composition at private centers

Read the full Poland report →

• Six or more major dedicated oncologic surgery centers including two ESMO-designated Centres (Wattanosoth 2025–2027, Chulabhorn 2021–2027 renewal)
• Da Vinci robotic surgical platforms at ≥5 centers with 2,500+ documented robotic cases at Siriraj over 12 years; advanced procedures including HIPEC, TORS, VATS, and MR-LINAC available
• Colorectal cancer 5-year overall survival 76.3% (colon) and 65.1% (rectal) at Siriraj—comparable to international benchmarks per published literature
• Fellowship-trained surgeons documented including Memorial Sloan Kettering and Singapore-trained physicians; Bumrungrad robotic team includes 12 cancer specialists across multiple subspecialties
• Comprehensive medical tourism infrastructure: multilingual support, care coordination, 3.5 million medical tourists in 2024, 60–70% cost savings versus Western pricing
• Strong international partnerships with MD Anderson Cancer Center and National Cancer Center Japan; multidisciplinary tumor boards standard at leading centers

Read the full Thailand report →

• Anadolu Medical Center achieved OECI accreditation in 2018, meeting 97% of European Cancer Association requirements as only OECI-accredited center in Turkey and surrounding region
• Turkey has 50+ JCI-accredited hospitals, the largest number among developing nations, with multiple specializing in oncology
• At least 8 hospitals equipped with da Vinci robotic surgical systems since 2007 for minimally invasive cancer procedures
• R0 resection rates documented at 78% for recurrent colorectal cancer, 75% for breast cancer, with D2 gastrectomy mortality of 3.3% in experienced centers
• Multidisciplinary tumor board approaches standard at major cancer centers (Anadolu, Memorial, Medipol); approximately 1 in 3 Turkish cancer doctors trained in Europe or USA
• Exceptional medical tourism infrastructure with 1.5 million international patients annually, dedicated international patient departments, multilingual staff, and 40-70% cost savings compared to USA/Western Europe
• However, surgical oncology not formally established as distinct subspecialty certification; geographic concentration of expertise in Istanbul, Ankara, Izmir; and lack of systematic public outcome reporting across all facilities and cancer types

Read the full Turkey report →

• 10+ major cancer centers with international accreditations: Sunway (ESMO Designated Centre 2025–2027, Newsweek ranked 26th Asia-Pacific oncology), SJMC (first Asia-Pacific hospital with four ACHS CoE certifications, 2025), Prince Court (JCI since 2009, serves 140+ countries), IKN, UMMC, Gleneagles, Pantai, KPJ, Island Hospital, Mahkota.
• 20+ fellowship-trained surgical oncologists documented across HPB (UMMC Assoc. Prof. Dr. Koh Peng Soon, Dr. Lee Yeong Sing; UKM fellowship), urologic oncology (Sunway Dr. Murali Sundram, Dr. Tan Guan Hee; UMMC), gynaecologic oncology (Sunway, IKN), colorectal/peritoneal oncology (Pantai Dr. Navinakathiresu—ESPSO Italy fellowship), and head/neck surgery (IKN, UMMC, Gleneagles).
• Only concrete published R0 resection rate: 58% for cholangiocarcinoma at UMMC (1997–2007 cohort, n=12 resected), below the 75–85% threshold for Score 4; no national surgical audit or current procedure-specific R0 data publicly available; colorectal cancer stage-specific 5-year survival at one tertiary hospital 67.9% (stage I+II) vs. national 18.4% (heavily influenced by 65.1% Stage 3–4 presentation rate).
• 12,000–15,000 estimated annual major cancer surgical procedures (based on ~33,764 new cancers/year and registry-documented 35–40% surgical utilization); Sunway robotic program alone logged 2,200+ cases over 7 years (all-specialty including oncology).
• Advanced surgical technology at multiple centers: Da Vinci Xi robotic surgery at 5+ hospitals; HIPEC available at Pantai KL and Gleneagles Penang (private sector) and public sector since February 2018; INTRABEAM intraoperative radiotherapy (Sunway); Gamma Knife (Gleneagles KL, 450+ cases since 2014); Varian TrueBeam STx, Radixact X9 Tomotherapy; no published data on dedicated hybrid ORs for cancer surgery.

Read the full Malaysia report →

• OECI-accredited National Institute of Oncology (Budapest) — only OECI center in Hungary and Central/Eastern Europe; operates 347 beds, treats 16,000 new cancer patients/year
• Network includes 4 regional university-based cancer centers (Debrecen, Pécs, Szeged, Szombathely) plus 19 county-level centers across Hungary
• Rapidly expanding robotic surgery program: da Vinci systems at 4 institutions; Semmelweis performed 450 robot-assisted oncological procedures in 2023/24
• IASIOS-accredited Semmelweis Onco-Interventional Department (first in Hungary/CEE) treating ~3,000 interventional oncology cases/year
• HIPEC program at Semmelweis with prospective research on 85 patients demonstrating improved survival outcomes for peritoneal metastases
• National Molecular Tumor Board (established 2019) provides nationwide multidisciplinary genetic profiling review accessible to all oncology centers
• Critical gap: R0 resection rates and perioperative mortality data not systematically published — no institutional outcome transparency
• Population-level outcomes significantly below EU average: Hungary has highest cancer mortality in EU (148.1/100,000), including worst mortality for lung, colorectal, breast, pancreatic cancers
• Surgical volumes appear 5,000–10,000 major cancer cases/year combined across major centers (lower end of Score 4 range)
• Specific counts of fellowship-trained oncologic surgeons not publicly reported, limiting assessment of specialist workforce

Read the full Hungary report →

• Four comprehensive cancer centers with advanced oncologic surgery (Cleveland Clinic Abu Dhabi, Burjeel Medical City, American Hospital Dubai, Tawam Hospital) plus Sheikh Shakhbout Medical City and Mediclinic City Hospital; but only 4 fellowship-trained surgical oncologists explicitly documented despite many surgeons lacking formal training
• Robotic surgical volumes of 1,800+ cumulative cases at American Hospital Dubai (≈500/year), 400+ at Cleveland Clinic Abu Dhabi in 2024, and 470+ at Burjeel Medical City; total major cancer surgery volumes not reported; well below Score 4 requirement of 5,000–10,000 annually
• Advanced technology including Da Vinci Xi and Da Vinci 5 robotic platforms, 1.5T intraoperative MRI (first in region), HIPEC, PIPAC, and histotripsy; pioneering procedures including first robotic cytoreductive surgery with HIPEC and first robotic mastectomy in UAE
• Burjeel Medical City holds ESMO accreditation (first and only in UAE), plus JCI, CARF, CAP, ISO 9001:2015; American Hospital Dubai is SRC-designated Center of Excellence in Robotic Surgery; Cleveland Clinic Abu Dhabi holds JCI, Magnet, ACGME, CAP; but outcomes data remain unpublished
• No national R0 resection rates, perioperative mortality, or comparative 5-year survival data publicly available; only scattered individual hospital outcome reports (e.g., Burjeel 88% OS for pediatric ALL); financial conflicts of interest documented as barrier to surgical oncology referrals in private sector

Read the full United Arab Emirates report →